Sanofi Announces Decision Not to Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

Дата публикации: 24-07-2026 01:07:28

Paris, July 24, 2026. Sanofi today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD). This decision not to submit for global regulatory reviews was...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)	0	16.04	06-08-2026
2	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	0	22.47	16-07-2026
3	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD	0	15.69	28-05-2026
4	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
5	Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod	0	18.01	30-07-2026
6	Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026	0	15.84	28-07-2026
7	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
8	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema	0	15.53	27-04-2026
9	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma	0	16.87	26-06-2026
10	Sobi Receives Complete Response Letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)	0	9.15	26-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.91. Источник: www.drugs.com.